Literature DB >> 21315556

Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).

Diego Bellavia1, Roshini S Abraham, Patricia A Pellikka, Angela Dispenzieri, John C Burnett, Ghormallah B Al-Zahrani, Tammy D Green, Michelle K Manske, Morie A Gertz, Fletcher A Miller, Theodore P Abraham.   

Abstract

BACKGROUND: Cardiac dysfunction is a well-recognized complication of light chain amyloidosis (AL). Autologous stem cell transplant (auto-SCT) has emerged as a successful treatment modality for AL patients. In this study, we examined the effect of clonal immunoglobulin light chain genes (VL), which encodes the immunoglobulin light chain protein that ultimately forms amyloid, on cardiac function, in the context of auto-SCT and its impact on overall survival.
METHODS: Longitudinal Doppler myocardial imaging parameters along with cardiac biomarkers were used to assess for cardiac function pre and post auto-SCT.
RESULTS: VL gene analysis revealed that Vl genes, in particular VlVI, were associated with worse cardiac function parameters than Vk genes. Clonal VL genes appeared to have an impact on left ventricular (LV) function post-transplant and also influenced mortality, with specific VL gene families associated with lower survival. Another key predictor of mortality in this report was change in tricuspid regurgitant flow velocity following auto-SCT. Correlations were also observed between systolic strain rate, systolic strain and VL genes associated with amyloid formation.
CONCLUSIONS: Clonal VL gene usage influences global cardiac function in AL, with patients having VlVI and VlII-III-associated amyloid more severely affected than those having Vk or VlI amyloid. Pulsed wave tissue Doppler imaging along with immunoglobulin gene analysis offers novel insights into prediction of mortality and cardiac dysfunction in AL after auto-SCT.
Copyright © 2011 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315556      PMCID: PMC3065954          DOI: 10.1016/j.echo.2011.01.003

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  31 in total

Review 1.  Diagnosis and management of the cardiac amyloidoses.

Authors:  Rodney H Falk
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

2.  Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis.

Authors:  A L Klein; L K Hatle; D J Burstow; C P Taliercio; J B Seward; R A Kyle; K R Bailey; M A Gertz; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1990-01       Impact factor: 24.094

Review 3.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

4.  Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis.

Authors:  C Tei; K S Dujardin; D O Hodge; R A Kyle; A J Tajik; J B Seward
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

5.  Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis.

Authors:  A L Klein; L K Hatle; C P Taliercio; C L Taylor; R A Kyle; K R Bailey; J B Seward; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

6.  Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.

Authors:  R L Comenzo; J Wally; G Kica; J Murray; T Ericsson; M Skinner; Y Zhang
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

7.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

8.  Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Tammy L Price-Troska; Cristine Allmer; Robert A Kyle; Morie A Gertz; Rafael Fonseca
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

9.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  VBASE2, an integrative V gene database.

Authors:  Ida Retter; Hans Helmar Althaus; Richard Münch; Werner Müller
Journal:  Nucleic Acids Res       Date:  2005-01-01       Impact factor: 16.971

View more
  7 in total

1.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

Review 2.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

3.  Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system.

Authors:  Francesco Cappelli; Samuele Baldasseroni; Franco Bergesio; Valentina Spini; Alessia Fabbri; Paola Angelotti; Elisa Grifoni; Paola Attanà; Francesca Tarantini; Niccolò Marchionni; Alberto Moggi Pignone; Federico Perfetto
Journal:  Intern Emerg Med       Date:  2016-08-01       Impact factor: 3.397

4.  Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy.

Authors:  Rahul Suresh; Martha Grogan; Joseph J Maleszewski; Patricia A Pellikka; Mazen Hanna; Angela Dispenzieri; Naveen L Pereira
Journal:  J Am Soc Echocardiogr       Date:  2014-01-18       Impact factor: 5.251

5.  IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.

Authors:  Surbhi Sidana; Surendra Dasari; Taxiarchis V Kourelis; Angela Dispenzieri; David L Murray; Rebecca L King; Ellen D McPhail; Marina Ramirez-Alvarado; Shaji K Kumar; Morie A Gertz
Journal:  Blood Adv       Date:  2021-04-27

Review 6.  Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance.

Authors:  Sujethra Vasu; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2013-07-31       Impact factor: 5.364

Review 7.  Cardiac Imaging in Systemic Diseases: What the Clinician should Know.

Authors:  Cesar J Herrera; Pamela Pina; Jorge Martinez; Mario J Garcia
Journal:  Curr Cardiol Rev       Date:  2018
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.